Trials / Terminated
TerminatedNCT06457997
A Study of PHN-010 in Patients With Advanced Solid Tumors
First-in-Human, Phase 1b Study of PHN-010, an Antibody Drug Conjugate, in Patients With Advanced Solid Tumors
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Pheon Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Conditions
- Lung Cancer
- Colon Cancer
- Endometrial Cancer
- Ovarian Cancer
- Cervical Cancer
- Advanced Solid Tumor
- Advanced Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PHN-010 | PHN-010 is an ADC |
Timeline
- Start date
- 2024-07-01
- Primary completion
- 2025-09-11
- Completion
- 2025-09-11
- First posted
- 2024-06-13
- Last updated
- 2026-01-29
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06457997. Inclusion in this directory is not an endorsement.